Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRWV NASDAQ:MDGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRWVCoreWeave$120.41+20.1%$116.64$33.51▼$187.00$58.83BN/A21.16 million shs54.11 million shsMDGLMadrigal Pharmaceuticals$436.83-2.7%$356.02$200.63▼$457.16$9.72B-1.02379,750 shs105,608 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRWVCoreWeave+7.13%+7.37%-22.64%-33.05%+10,021,999,900.00%MDGLMadrigal Pharmaceuticals-1.12%+2.89%+29.79%+52.45%+88.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRWVCoreWeave$120.41+20.1%$116.64$33.51▼$187.00$58.83BN/A21.16 million shs54.11 million shsMDGLMadrigal Pharmaceuticals$436.83-2.7%$356.02$200.63▼$457.16$9.72B-1.02379,750 shs105,608 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRWVCoreWeave+7.13%+7.37%-22.64%-33.05%+10,021,999,900.00%MDGLMadrigal Pharmaceuticals-1.12%+2.89%+29.79%+52.45%+88.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRWVCoreWeave 2.37Hold$107.457.22% UpsideMDGLMadrigal Pharmaceuticals 2.90Moderate Buy$471.134.99% UpsideCurrent Analyst Ratings BreakdownLatest CRWV and MDGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025MDGLMadrigal PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$500.008/26/2025CRWVCoreWeaveCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$116.008/26/2025MDGLMadrigal PharmaceuticalsCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/26/2025CRWVCoreWeaveCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$116.008/26/2025MDGLMadrigal PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$390.00 ➝ $554.008/21/2025CRWVCoreWeaveArete ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/21/2025CRWVCoreWeaveAreteSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$180.008/21/2025CRWVCoreWeaveHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$180.008/20/2025MDGLMadrigal PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$483.00 ➝ $485.008/19/2025CRWVCoreWeaveMoffett NathansonSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$56.00 ➝ $65.008/14/2025CRWVCoreWeaveArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$200.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRWVCoreWeaveN/AN/AN/AN/AN/AN/AMDGLMadrigal Pharmaceuticals$180.13M55.30N/AN/A$34.59 per share12.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRWVCoreWeaveN/AN/A0.00∞N/AN/AN/AN/AN/AMDGLMadrigal Pharmaceuticals-$465.89M-$12.85N/AN/AN/A-54.68%-38.38%-27.32%10/30/2025 (Estimated)Latest CRWV and MDGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025CRWVCoreWeave-$0.20-$0.27-$0.07-$0.60N/A$1.21 million8/5/2025Q2 2025MDGLMadrigal Pharmaceuticals-$3.48-$1.90+$1.58-$1.90$158.94 million$212.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRWVCoreWeaveN/AN/AN/AN/AN/AMDGLMadrigal PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRWVCoreWeave2.790.520.52MDGLMadrigal Pharmaceuticals0.175.114.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRWVCoreWeaveN/AMDGLMadrigal Pharmaceuticals98.50%Insider OwnershipCompanyInsider OwnershipCRWVCoreWeaveN/AMDGLMadrigal Pharmaceuticals21.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRWVCoreWeave881488.57 millionN/AN/AMDGLMadrigal Pharmaceuticals9022.20 million17.43 millionOptionableCRWV and MDGL HeadlinesRecent News About These CompaniesCoreWeave and Madrigal's Insider Trades Flash Bullish Signals (MDGL)...September 10 at 7:31 AM | marketbeat.comMadrigal Pharmaceuticals (NASDAQ:MDGL) CEO William John Sibold Sells 7,279 SharesSeptember 10 at 5:38 AM | insidertrades.comA Fresh Look at Madrigal Pharmaceuticals (MDGL) Valuation Following Recent Share Price MomentumSeptember 9 at 9:03 AM | finance.yahoo.comWhat is HC Wainwright's Forecast for MDGL Q3 Earnings?September 9 at 2:10 AM | marketbeat.comMadrigal Pharmaceuticals, Inc. (MDGL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 8 at 11:01 AM | seekingalpha.comCinctive Capital Management LP Reduces Position in Madrigal Pharmaceuticals, Inc. $MDGLSeptember 8 at 5:47 AM | marketbeat.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Receives Buy Rating from HC WainwrightSeptember 6, 2025 | marketbeat.comCutter Capital Management LP Purchases New Shares in Madrigal Pharmaceuticals, Inc. $MDGLSeptember 6, 2025 | marketbeat.comAllostery Investments LP Buys Shares of 600 Madrigal Pharmaceuticals, Inc. $MDGLSeptember 5, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Has $63.47 Million Holdings in Madrigal Pharmaceuticals, Inc. $MDGLSeptember 5, 2025 | marketbeat.comMadrigal Pharmaceuticals assumed with a Buy at H.C. WainwrightSeptember 4, 2025 | msn.comTD Cowen Sees Greater Upside in Madrigal (MDGL) Following Recent Rezdiffra ApprovalSeptember 4, 2025 | msn.comMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)September 4, 2025 | globenewswire.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Sets New 52-Week High - What's Next?September 4, 2025 | marketbeat.comADAR1 Capital Management LLC Invests $494,000 in Madrigal Pharmaceuticals, Inc. $MDGLSeptember 4, 2025 | marketbeat.comMPM Bioimpact LLC Makes New Investment in Madrigal Pharmaceuticals, Inc. $MDGLSeptember 4, 2025 | marketbeat.comQuarry LP Invests $232,000 in Madrigal Pharmaceuticals, Inc. $MDGLSeptember 4, 2025 | marketbeat.comMadrigal Pharmaceuticals to Participate in Morgan Stanley 23rd Annual Global Healthcare ConferenceSeptember 3, 2025 | globenewswire.comPaulson & CO. Inc. Grows Stake in Madrigal Pharmaceuticals, Inc. $MDGLSeptember 3, 2025 | marketbeat.com48,690 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Purchased by Braidwell LPSeptember 3, 2025 | marketbeat.comMadrigal Pharmaceuticals, Inc. $MDGL is Propel Bio Management LLC's 2nd Largest PositionSeptember 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025CoreWeave Pulls Back Into a Screaming BuyBy Thomas Hughes | August 13, 2025CoreWeave and Madrigal's Insider Trades Flash Bullish SignalsBy Leo Miller | September 10, 2025CRWV and MDGL Company DescriptionsCoreWeave NASDAQ:CRWV$120.13 +19.91 (+19.87%) As of 01:40 PM EasternCoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.Madrigal Pharmaceuticals NASDAQ:MDGL$435.51 -13.22 (-2.95%) As of 01:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing Beyond DIY: Home Depot's Conquest of the Professional Market Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
